Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Checked for new insider filings 2 h ago
Guides: What is an SEC Form 4 · the transaction codes · who has to file · 10b5-1 plans
Worth a look: purchases of $10K+ and sales of $250K+ not reported under a pre-arranged trading plan.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade
A major shareholder of Expensify sold $319K of Expensify shares. The filing does not indicate a pre-arranged trading plan.
Lately at Expensify: it reported its results on Nov 5; the stock is down 44% in 30 days; insiders made no purchase ($10K+) and 6 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −0.4% · S&P 500 −9.2% · to Nov 20
Chemed's executive vice president sold $548K of Chemed shares. The filing does not indicate a pre-arranged trading plan.
Lately at Chemed Corp.: it reported its results on Oct 27; the stock is up 7% in 30 days; insiders made no purchase ($10K+) and 7 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −5.3% · S&P 500 −8.9% · to Nov 20
GATX's Sr. VP & Controller sold $479K of GATX shares. The filing does not indicate a pre-arranged trading plan.
Lately at GATX: it signed an important agreement on Nov 18; the stock is up 9% in 30 days; insiders made no purchase ($10K+) and 5 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 13 · filed the same dayNot reported under a pre-arranged trading plan
Since the trade −11.0% · S&P 500 −8.6% · to Nov 20
Estée Lauder's Exec VP GlobalComm/PubAffairs sold $468K of Estée Lauder shares. The filing does not indicate a pre-arranged trading plan.
Lately at Estée Lauder Companies (The): it reported its results on Nov 2; insiders made no purchase ($10K+) and 18 large sales ($250K+, not pre-arranged) in 90 days; members of Congress disclosed 2 purchases and no sale in 90 days.
Insider selling
Traded Nov 9 · filed 4 days laterNot reported under a pre-arranged trading plan
Since the trade −5.9% · S&P 500 −8.3% · to Nov 20
A South Plains Financial director sold $349K of South Plains Financial shares. The filing does not indicate a pre-arranged trading plan.
Lately at South Plains Financial: it reported its results on Oct 22; the stock is down 7% in 30 days; insiders made no purchase ($10K+) and 5 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −3.2% · S&P 500 −8.9% · to Nov 20
EXL Service's President of EXL sold $465K of EXL Service shares. The filing does not indicate a pre-arranged trading plan.
Lately at EXL Service: it reported its results on Oct 27; insiders made no purchase ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −17.9% · S&P 500 −8.9% · to Nov 20
Viavi Solutions's Chief Mktg & Stgy Officer sold $443K of Viavi Solutions shares. The filing does not indicate a pre-arranged trading plan.
Lately at Viavi Solutions: it reported its results on Nov 4; the stock is down 25% in 30 days; insiders made no purchase ($10K+) and 4 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 13 · filed the same dayNot reported under a pre-arranged trading plan
Since the trade −5.3% · S&P 500 −8.6% · to Nov 20
A Molina Healthcare director sold $330K of Molina Healthcare shares. The filing does not indicate a pre-arranged trading plan.
Lately at Molina Healthcare: the stock rose 11% in one session on Nov 16 with press coverage; it reported its results on Oct 21; the stock is down 8% in 30 days.
Insider selling
Traded Nov 13 · filed the same dayNot reported under a pre-arranged trading plan
Since the trade −3.8% · S&P 500 −8.6% · to Nov 20
An ICU Medical director sold $304K of ICU Medical shares. The filing does not indicate a pre-arranged trading plan.
Lately at ICU Medical: it reported its results on Nov 5; the stock is up 7% in 30 days.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −15.3% · S&P 500 −9.2% · to Nov 20
A Xometry director sold $310K of Xometry shares. The filing does not indicate a pre-arranged trading plan.
Lately at Xometry: the stock rose 17% in one session on Nov 3 around a company release; it reported its results on Nov 3; the stock is up 17% in 30 days.
Insider selling
Traded Nov 10 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −0.7% · S&P 500 −8.0% · to Nov 20
An Amdocs director sold $306K of Amdocs shares. The filing does not indicate a pre-arranged trading plan.
Lately at Amdocs: the stock fell 30% in one session on Nov 4 with press coverage; the stock is down 33% in 30 days; insiders made 7 purchases ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade +1.6% · S&P 500 −9.2% · to Nov 20
A Mirum Pharmaceuticals director sold $309K of Mirum Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
Lately at Mirum Pharmaceuticals: the stock rose 11% in one session on Nov 4 around a company release; it reported its results on Nov 3; the stock is up 15% in 30 days.
Insider selling
Traded Apr 14 · filed 213 days laterNot reported under a pre-arranged trading plan
Since the trade +4.5% · S&P 500 −0.7% · to Nov 20
A Valley Bank director sold $300K of Valley Bank shares. The filing does not indicate a pre-arranged trading plan.
Lately at Valley Bank: it reported its results on Oct 22; the stock is up 5% in 30 days.
Insider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −10.2% · S&P 500 −8.9% · to Nov 20
Flowco's Natural Gas Technologies sold $370K of Flowco shares. The filing does not indicate a pre-arranged trading plan.
Lately at Flowco: it reported its results on Nov 4; the stock is 33% below its 12-month high; insiders made 5 purchases ($10K+) and 1 large sale ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 11 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade −10.9% · S&P 500 −9.2% · to Nov 20
Arxis's See Remarks sold $332K of Arxis shares. The filing does not indicate a pre-arranged trading plan.
Lately at Arxis: the stock is down 6% in 30 days; insiders made no purchase ($10K+) and 3 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 12 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −3.8% · S&P 500 −8.9% · to Nov 20
Sally Beauty's SVP, CLO and CHRO sold $291K of Sally Beauty shares. The filing does not indicate a pre-arranged trading plan.
Lately at Sally Beauty Holdings, Inc.: it reported its results on Nov 10; the stock is up 7% in 30 days; insiders made no purchase ($10K+) and 2 large sales ($250K+, not pre-arranged) in 90 days.
Insider selling
Traded Nov 13 · filed the same dayNot reported under a pre-arranged trading plan
Since the trade −7.6% · S&P 500 −8.6% · to Nov 20
EnPro Industries's SVP, Controller and CAO sold $280K of EnPro Industries shares. The filing does not indicate a pre-arranged trading plan.
Lately at EnPro Industries, Inc.: it reported its results on Nov 3; the stock is down 14% in 30 days.
Insider buying
5 insiders in a week, a first since 2020Traded Nov 9 · filed 3 days later
Since the trade +15.4% · S&P 500 −8.3% · to Nov 20
Bought 10% below the 52-week high, RSI 49, 24% above its 200-day average, 32 points ahead of the S&P 500 over 3 months
A major shareholder of Orchestra Biomed paid $6M out of pocket for Orchestra Biomed shares. 4 other people at Orchestra Biomed bought some too, in the same month. It was the first purchase in 19 months.
Lately at Orchestra Biomed Holdings: the stock rose 18% in one session on Nov 13 with press coverage; it signed an important agreement on Nov 9; the stock is up 13% in 30 days.
Insider buying
Traded Nov 10 · filed 2 days later
Since the trade −13.8% · S&P 500 −8.0% · to Nov 20
Bought 40% below the 52-week high, RSI 75, 13% under its 200-day average, 12 points behind the S&P 500 over 3 months
The CEO of Ftai Infrastructure paid $1.53M out of pocket for Ftai Infrastructure shares. 1 other person at Ftai Infrastructure bought some too, in the same month. It was the first purchase in 18 months.
Lately at Ftai Infrastructure: the stock rose 18% in one session on Nov 6 around a company release; it signed an important agreement on Nov 17; the stock is up 37% in 30 days.
Insider buying
3 insiders in a week, a first since 2020Traded Nov 10 · filed 2 days later
Since the trade −6.9% · S&P 500 −8.0% · to Nov 20
Bought 50% below the 52-week high, RSI 39, 33% under its 200-day average, 30 points behind the S&P 500 over 3 months
A MP Materials director paid $1.98M out of pocket for MP Materials shares. 2 other people at MP Materials bought some too, in the same month. Shares held went up 36% with this purchase.
Lately at MP Materials: it reported its results on Nov 5; the stock is down 14% in 30 days; insiders made 8 purchases ($10K+) and no large sale ($250K+, not pre-arranged) in 90 days.